Cladribine, Cyclophosphamide, and Rituximab for the Primary Treatment of Macroglobulinemic Lymphoma

This phase I trial studies how well cladribine, cyclophosphamide, and rituximab work for the primary treatment of macroglobulinemic lymphoma. Drugs used in chemotherapy, such as cladribine and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with rituximab, may induce changes in body’s immune system and may interfere with the ability of cancer cells to grow and spread. Giving cladribine, cyclophosphamide, and rituximab may work better in shrinking lymphoma cells compared to each drug by itself.

Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT00667329.

Trial PhasePhase I

Trial Typetreatment

Lead OrganizationM D Anderson Cancer Center

Principal InvestigatorDonna M. Weber

• Primary IDDM99-070
• Secondary IDsNCI-2020-00334
• ClinicalTrials.gov IDNCT00667329